Treprostinil Palmitil Inhalation Powder

Phase 3

Insmed Incorporated (INSM)

00%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

2mo

INSM⭐Phase 3$11.0B

Treprostinil Palmitil Inhalation Powder Phase 3 Results Expected

Treprostinil Palmitil Inhalation Powder• Pulmonary Hypertension31

Mar 14

CT.gov

00%

Drug Information

Target Indication

Pulmonary Hypertension

Clinical Trial

NCT05649722

Last updated: 12/4/2025

Regulatory Approvals

EMAPending

Treprostinil SciPharm Sàrl

Treatment of chronic thromboembolic pulmonary hypertension

View on EMA

EMA4/3/2020

Trepulmix

Treatment of adult patients with WHO Functional Class (FC) III or IV and: inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment to improve exercise capacity.

Orphan

View on EMA

Developer

INSM

Insmed Incorporated

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.Phase 3

Pseudomonas Aeruginosa Infection

LAI 590 mgPhase 3

NTM Lung Infection Due to MAC

Liposomal amikacin for inhalationPhase 3

Cystic Fibrosis

Brensocatib 25 mgPhase 3

Non-Cystic Fibrosis Bronchiectasis

Treprostinil PalmitilPhase 3

Pulmonary Hypertension

View full pipeline